NASDAQ · Biotechnology

89bio, Inc. (ETNB) Stock

$14.84 +0.00% NASDAQ: ETNB Healthcare

Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system.

Valuation

MetricValue
Price$14.84
Market Cap$2.20B
P/E Ratio-12.82
P/B Ratio4.49
P/S Ratio0.00
EPS (TTM)$-3.51
52-Week High$15.06
52-Week Low$4.16
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-32.43%
ROA-30.29%
ROCE-34.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.07
Current Ratio15.19

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0$0
Operating Profit$-49.0M$-90.0M$102.0M$-151.0M$-385.0M
Net Profit$-49.0M$-90.0M$-102.0M$-142.0M$-367.0M
EPS$-3.08$-4.48$-2.93$-2.00$-3.51
Op Margin—————

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$211.0M$162.0M$197.0M$596.0M$479.0M
Total Liabilities$8.0M$36.0M$45.0M$60.0M$78.0M
Cash$98.0M$52.0M$55.0M$316.0M$126.0M
Borrowings$0$19.0M$21.0M$27.0M$38.0M

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-46.0M$-77.0M$-81.0M$-129.0M$-368.0M
Investing Cash Flow$-107.0M$7.0M$-34.0M$-246.0M$-82.0M
Financing Cash Flow$0$0$1.0M$14.0M$52.0M
Net Cash Flow$5.0M$-46.0M$3.0M$261.0M$-190.0M
Free Cash Flow$-46.0M$-77.0M$-81.0M$-129.0M$-368.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.22
EV / EBITDA-11.59
FCF Yield-7.83%
Quick Ratio15.19
Interest Coverage-79.76
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGIO $31.72 +0.38% -3.56 $1.89B 0.00%
BEAM $25.62 +2.19% -35.36 $2.64B 0.00%
COGT $42.27 -1.33% -34.70 $7.22B 0.00%
DNLI $24.42 +1.03% -6.20 $3.88B 0.00%
GLPGGalapagos N.V. $27.98 +1.71% 3.57 $1.84B 0.00%

About 89bio, Inc.

Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.

89bio, Inc. is headquartered in US.

89bio, Inc. (ETNB) stock trades at $14.84 with a market capitalization of $2.20B. The stock is valued at a price-to-earnings (P/E) ratio of -12.82, price-to-book of 4.49, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.16 and $15.06, and currently trades 1.5% below its 52-week high.

On profitability, 89bio, Inc. generates a return on equity (ROE) of -32.43%, return on capital employed of -34.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.89bio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides